1. Proactive One2One Healthcare Forum July 11th 2019
Clinigen Group
Proactive One2One Healthcare Forum
July 11th 2019

2. Introducing Clinigen – a UK Based global company
A unique combination of businesses with an International platform

3. Introducing Clinigen – growth profile
A strong track record of expansion through products, capabilities and infrastructure
Adjusted gross profit
Adjusted EBITDA
Adjusted gross profit: 25% GROWTH VS H1 18
QUANTUM & IMMC ACQUIRED
LINK ACQUIRED
TOTECT ACQUIRED
CSM & iQONE ACQUIRED
PROLEUKIN US/RoW ACQUIRED
IMUKIN ACQUIRED
46% CAGR GROWTH IN GROSS PROFIT
61% CAGR GROWTH IN EBITDA
£80M
SAVENE & ETHYOL ACQUIRED
IDIS ACQUIRED
CARDIOXANE ACQUIRED
LIST ON AIM
GROUP FORMED
FOSCAVIR ACQUIRED
PHASE 01
PHASE 02
PHASE 03
Consolidation of initial business, acquisition of additional assets
Build infrastructure, development of global vision
Global positioning, differentiation of businesses, genuine lifecycle partnership
* Adjusted results exclude amortisation of acquired intangibles and products, and other non-underlying items relating to acquisitions. Adjusted EBITDA includes the Group’s share of EBITDA from its joint venture. Adjusted results include amortisation of software and internally developed IP. CAGR growth covers the eight year period between FY10 and FY18

4. Change in last 12 months CSM
Increases size of customer base at early stage of product lifecycle.
Additional capabilities that enhance propositions across all businesses.
IQone
Provides capability to support Clinigen and MA partner products.
Growing a capability to commercialise products earlier in lifecycle.
Proleukin and Imukin Acquisitions
Niche, biologic products, limited risk of generic alternatives.
Proleukin extensively used in clinical studies across the world.
Creation of Clinigen Inc Commercial Medicines group.
Launch of new online portal as part of overall Digital Strategy.

5. Proleukin Multiple revitalisation opportunities Regulatory
Transitioning global Marketing Authorisations from Novartis to Clinigen, incl. US, EU and Row.
Ability to manage unlicensed supply in other markets
Manufacturing
Development of new presentations and dosage forms of IL-2
Collaboration on multiple cell therapy manufacturing programs worldwide
Clinical development
New indication using low dose in Immunology (ALS, GVHD, LUPUS, Type I Diabetes, UC, MS, Transplant)
High dose in Oncology (continued development of high dose IL-2 therapy in oncology)
TIL and CAR-T
Multiple revitalisation opportunities

6. EXTENDED GLOBAL FOOTPRINT
UK: Burton-on-Trent
Weybridge
London
Newcastle
USA:
Yardley | Malvern | Exton (PA) Fargo (ND) | Nashville (TN)
HONG KONG SINGAPORE
EUROPE: ireland
SwitzerlanD
Belgium
Germany
France
greece
INTERNATIONAL LOCATIONS 14
COUNTRIES SUPPLIED
108
UNITS SHIPPED
4.3M
JAPAN
SOUTH AFRICA
AUSTRALIA
NEW ZEALAND

7. THE INVESTMENT CASE UNIQUE COMBINATION OF BUSINESSES
EXTENDING ACROSS PHARMA PRODUCT LIFECYCLE WITH CLEAR SYNERGIES
MARKET-LEADING POSITIONS
#1 IN CTS AND UNLICENSED MEDICINES
SIGNIFICANT LONG-TERM GROWTH POTENTIAL
BOTH ORGANIC AND ACQUISITIONAL GROWTH OPPORTUNITY
HIGHLY CASH GENERATIVE
WITH STRONG CREDIT CONTROL AND WORKING CAPITAL MANAGEMENT
UNPARALLELED KNOWLEDGE AND EXPERTISE
IN SUPPLY AND DISTRIBUTION OF UNLICENSED MEDICINES
GLOBAL CAPABILITY
SUPPLYING INTO OVER 100 COUNTRIES
TRUSTED ETHICAL SUPPLIER
DEEP RELATIONSHIPS WITH PHYSICIANS AND BIG PHARMA
EXPERIENCED MANAGEMENT TEAM
TRACK RECORD OF DELIVERING STRONG GROWTH

8. Right Medicine. Right Patient. Right Time
Q&A
Right Medicine. Right Patient. Right Time